Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according to ...
BioWorld - Friday, October 3, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » A single antibody to attack two epitopes ...
For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results